ArticlePLoS neglected tropical diseases2018
Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico.
Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Evaluation of the immune response against Trypanosoma cruzi cytosolic tryparedoxin peroxidase in human natural infection.Immunology · 2018Trial
- Epitope mapping of vaccine antigens Tc24 and TSA1 with antibodies from Trypanosoma cruzi-infected patients.Genes and immunity · 2026Article
- Rapid High-Sensitivity Detection of Antibodies to Trypanosoma cruzi With a Recombinant Tc24 Antigen-Based Magneto-Immunoassay: A Pilot Study.The Journal of infectious diseases · 2025Article
- Immunogenicity ofPathogens (Basel, Switzerland) · 2025Article
- The Functions of Cytokines in the Cardiac Immunopathogenesis of Chagas Disease.Pathogens (Basel, Switzerland) · 2024Review
- Chagas Disease: A Silent Threat for Dogs and Humans.International journal of molecular sciences · 2024Review
- Review
- Review
- Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi.PLoS neglected tropical diseases · 2021Article
- α-Gal immunization positively impacts Trypanosoma cruzi colonization of heart tissue in a mouse model.PLoS neglected tropical diseases · 2021Article
- Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection.Scientific reports · 2021Article
- The Case for the Development of a Chagas Disease Vaccine: Why? How? When?Tropical medicine and infectious disease · 2021Review
- T Cell Specificity: A Great Challenge in Chagas Disease.Frontiers in immunology · 2021Review
- Extent of polymorphism and selection pressure on theEvolutionary applications · 2020Article
- Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques.Vaccine · 2020Article
- Current trends in the pharmacological management of Chagas disease.International journal for parasitology. Drugs and drug resistance · 2020Review
- Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine AgainstFrontiers in immunology · 2020Article
- Immunity and vaccine development efforts against Trypanosoma cruzi.Acta tropica · 2019Review
- A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease.NPJ vaccines · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trypanosoma cruzi antigens TSA-1 and Tc24 have shown promise as vaccine candidates in animal studies. We evaluated here the recall immune response these antigens induce in Chagasic patients, as a first step to test their immunogenicity in humans. We evaluated the in vitro cellular immune response after stimulation with recombinant TSA-1 (rTSA-1) or recombinant Tc24 (rTc24) in mononuclear cells of asymptomatic Chagasic chronic patients (n = 20) compared to healthy volunteers (n = 19) from Yucatan, Mexico. Proliferation assays, intracellular cytokine staining, cytometric bead arrays, and memory T cell immunophenotyping were performed by flow cytometry. Peripheral blood mononuclear cells (PBMC) from Chagasic patients showed significant proliferation after stimulation with rTc24 and presented a phenotype of T effector memory cells (CD45RA-CCR7-). These cells also produced IFN-γ and, to a lesser extent IL10, after stimulation with rTSA-1 and rTc24 proteins. Overall, both antigens recalled a broad immune response in some Chagasic patients, confirming that their immune system had been primed against these antigens during natural infection. Analysis of HLA-A and HLA-B allele diversity by PCR-sequencing indicated that HLA-A03 and HLA-B07 were the most frequent supertypes in this Mexican population. Also, there was a significant difference in the frequency of HLA-A01 and HLA-A02 supertypes between Chagasic patients and controls, while the other alleles were evenly distributed. Some aspects of the immune response, such as antigen-induced IFN-γ production by CD4+ and CD8+ T cells and CD8+ proliferation, showed significant association with specific HLA-A supertypes, depending on the antigen considered. In conclusion, our results confirm the ability of both TSA-1 and Tc24 recombinant proteins to recall an immune response induced by the native antigens during natural infection in at least some patients. Our data support the further development of these antigens as therapeutic vaccine against Chagas disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.